Sector
PharmaceuticalsOpen
₹1,374Prev. Close
₹1,376.5Turnover(Lac.)
₹13,255.58Day's High
₹1,391.4Day's Low
₹1,371.152 Week's High
₹1,67352 Week's Low
₹1,165.7Book Value
₹423.36Face Value
₹2Mkt Cap (₹ Cr.)
1,11,240.3P/E
32.3EPS
42.61Divi. Yield
0.9413 May 2025
12:00 AM
AGM
Announcement Date: 13 May, 2025
31 Mar 2026
12:00 AM
Board Meeting
Agenda : Audited Result
13 May 2026
12:00 AM
Dividend
Dividend Amount: 13
Record Date: 05 Jun, 2026
At around 3.27 PM, Cipla was trading 3.90% lower at ₹1,316.90 per piece, against the previous close of ₹1,370.40 on NSE.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Tirzepatide acts on both GIP and GLP-1 receptors and is prescribed along with diet and exercise for adults with obesity, defined as a BMI of 30 or higher.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
iCaltech, an ISO 13485-certified medical device company, is engaged in the design, development and commercialisation of diagnostic products with a strong focus on respiratory applications
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 161.56 | 161.52 | 161.47 | 161.43 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 34,039.55 | 31,937.72 | 27,812.45 | 24,476.66 |
Net Worth | 34,201.11 | 32,099.24 | 27,973.92 | 24,638.09 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,126.76 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 27,711.69 | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,711.69 | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 |
Other Operating Income | 450.9 | 402.22 | 327.46 | 279.94 | 139.98 |
Other Income | 882.01 | 861.87 | 746.57 | 475.45 | 280.91 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,786.4 | 142.85 | 4,28,785.15 | 608.7 | 0.9 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,638.5 | 66.2 | 1,76,241.94 | 756 | 0.45 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,463.7 | 68.28 | 1,51,058.35 | 467 | 0.85 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,377 | 32.3 | 1,11,179.71 | 384.64 | 0.94 | 3,840.92 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,098.3 | 29.92 | 1,10,474.43 | 1,722 | 0.09 | 3,564.6 | 235.25 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Y K Hamied
Vice Chairman / Independent Non Executive Director
P R Ramesh
Non-Exec & Non-Independent Dir
Kamil Hamied
Non-Exec & Non-Independent Dir
Abhijit J. Joshi
Non-Exec & Non-Independent Dir
Adil Zainulbhai
Independent Non Exe. Director
Dr Balram Bhargava
Independent Non Exe. Director
Mandar Purushottam Vaidya
Independent Non Exe. Director
MAYA HARI
Independent Non Exe. Director
SHARMILA NITIN PARANJPE
MD / Global CEO / Global COO
Achin Gupta
Company Sec. & Compli. Officer
Rajendra Chopra
Cipla House Peninsula Buss Par,
Ganpatrao Kadam Mg Lower Parel,
Maharashtra - 400013
Tel: 91-22-24826000
Website: http://www.cipla.com
Email: cosecretary@cipla.com, contactus@cipla.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Cipla Ltd is one of India’s oldest and most trusted pharmaceutical companies, advancing affordable healthcare and developing a large global portfolio of medicines, APIs and complex therapies.
Company ...
Read More
Reports by Cipla Ltd
What is the Cipla Ltd share price today?
What is the Market Cap of Cipla Ltd?
What is the PE and PB ratio of Cipla Ltd?
What is the 52 Week High and Low of Cipla Ltd?
What is the CAGR of Cipla Ltd?
What is the shareholding pattern of Cipla Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
